Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

By S. Picard, K. Titier, G. Étienne, E. Teilhet, D. Ducint, M. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Bégaud and 3 more. Blood, 2007

630 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/3da71cbbdf4881d3f646790afad1362e56866275

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Brian J. Druker

In Hematology

1. Brian J. Druker
2. J. Goldman
3. J. Apperley

In Rheumatology

1. Brian J. Druker

Citations in the corpus

• Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. (2008, background): “cytogenetic and molecular responses.(14) In the present study, plasma trough levels of imatinib at steady state following the first month of treatment (Day 29) also proved to be”
• Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010, methodology): “Trough imatinib plasma levels were measured as previously reported.(21) Patients who took the imatinib in the evenings were instructed to take it in the mornings for the 3 days before the clinic visit.”